EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION
https://doi.org/10.21292/2075-1230-2017-95-9-49-54
Abstract
The goal of the study: to evaluate efficiency and safety of the anti-tuberculosis drug of bedaquiline in the multimodality therapy of patients with HIV-associated tuberculosis with multiple/extensive drug resistance (MDR/XDR).
Materials and methods. 14 patients were treated with the regimens containing bedaquiline. The majority of patients (12; 85.7%) received antiretroviral therapy. 11 (78.6%) patients were diagnosed with the generalized form of tuberculosis affecting two organs and more. All 14 patients were infectious: 2 had MDR TB and 12 had XDR TB, and of them, 11 had XDR TB with resistance to 8-10 anti-tuberculosis drugs.
Results. 12 out of 14 patients completed the intensive phase with administration of bedaquiline. By the end of the first month of treatment intoxication symptoms disappeared in 50.0% of patients, and by the end of the second month, they remitted in 83.5%. The positive X-ray changes were observed in 50% of patients, and they manifested through the partial resolution of focal infiltrate changes in the lungs. Cessation of bacillary excretion was documented by the end of the second month in 6 patients, by the end of the 3rd month in 1 patient, by the end of the 6th month in 3 patients, totally in 10 out of 12 patients (83.3%). During treatment, all patients had an electrocardiogram, and none of them had prolongation of QT interval.
About the Author
G. S. BALASANYANTS
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Associate Professor of Phthisiology Department
9, Akademika Lebedeva St., St. Petersburg, 194044
References
1. Use guidelines for Sirturo. LP-002281, 17.07.2015. (In Russ.)
2. Federal clinical recommendations for diagnosis and treatment of respiratory tuberculosis with multiple drug resistance. Moscow, Triada Publ., 2014. 72 p.
3. Borisov S.E., Dheda K., Enwerem M. et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur. Respir. J., 2017, vol. 49: 1700387
4. Dheda K., Esmail A., Limberis J., Maartens† G. Selected questions and controversies about bedaquiline: a view from the field. Int. J. Tuberc. Lung Dis., vol. 20, no. 12, pp. S24-S32.
5. Dheda K., Shean K., Zumla A. et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet, 2010, vol. 375. pp. 1798-1807.
6. Gopalan N., Chandrasekaran P., Swaminathan S., Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res. Therap., 2016, vol. 13, pp. 34.
7. Migliori G.B., Sotgiu G., Gandhi N. R. et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur. Respir. J., 2013, vol. 42, pp. 169-179.
8. Ndjeka N., Conradie F., Schnippel K. et al. Treatment of drugresistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int. J. Tuberc. Lung Dis., 2015, vol. 19, pp. 979-985.
9. Orenstein E.W., Basu S., Shah N.S., Andrews J.R., Friedland G.H., Moll A.P. et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis., 2009, vol. 9, pp. 153-161.
10. Pandie M., Wiesner L., McIlleron H. et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV- infected patients with drug-resistant TB. J. Antimicrob. Chemother., 2016, vol. 71, pp. 1037-1040.
11. Pietersen E., Ignatius E., Streicher E.M. et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet, 2014, vol. 383, pp. 1230-1239.
12. Treatment Guidelines for Drug-Resistant Tuberculosis, 2016, Geneva, World Health Organisation, 2016.
13. Veziris N., Bernard Ch., Guglielmetti L. et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Eur. Respir. J., 2017, vol. 49: 1601719; DOI: 10.1183/13993003.01719-2016.
14. World Health Organization. Guidelines for the programmatic management of drug- resistant tuberculosis: 2011 update. Geneva, World Health Organization; 2011.
Review
For citations:
BALASANYANTS G.S. EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION. Tuberculosis and Lung Diseases. 2017;95(9):49-54. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-9-49-54
Views:
1340
Email this article 